Biostar Pharmaceuticals Inc (BSPM) financial statements (2020 and earlier)

Company profile

Business Address NO. 588 SHIJI XI AVENUE
XIANYANG, SHAANXI PROVINCE, 712046
State of Incorp. MD
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2017
TTM
12/31/2016
12/31/2015
12/31/2014
12/31/2013
12/31/2012
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 00202
Cash and cash equivalents 00202
Receivables 71627231
Inventory, net of allowances, customer advances and progress billings 00111
Inventory 00111
Prepaid expense 0 4 
Advances on inventory purchases    1 
Prepaid expense and other current assets8
Income taxes receivable00
Other undisclosed current assets   1032 
Total current assets: 716443642
Noncurrent Assets
Property, plant and equipment 67887
Intangible assets, net (including goodwill) 6713179
Intangible assets, net (excluding goodwill) 6713179
Prepaid expense    4
Deposits noncurrent assets 2116949
Other undisclosed noncurrent assets 3573546
Total noncurrent assets: 3535386870
TOTAL ASSETS: 435181104112
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 34501
Accounts payable 345  
Taxes payable  0001
Debt 233 5
Derivative instruments and hedges, liabilities 000  
Due to related parties     2
Other undisclosed current liabilities    46
Total current liabilities: 679513
Noncurrent Liabilities
Total liabilities: 679513
Stockholders' equity
Stockholders' equity attributable to parent, including: 3744726358
Common stock 00000
Additional paid in capital 3130302623
Deferred compensation equity    (0) 
Accumulated other comprehensive income 13675
Retained earnings (accumulated deficit) (3)3282423
Other undisclosed stockholders' equity attributable to parent 77777
Total stockholders' equity: 3744726358
TOTAL LIABILITIES AND EQUITY: 4351816870

Income statement (P&L) ($ in millions)

9/30/2017
TTM
12/31/2016
12/31/2015
12/31/2014
12/31/2013
12/31/2012
Revenues
(Revenue, Net)
 227615349
Cost of revenue
(Cost of Goods and Services Sold)
 (1)(16)(31)(27)(19)
Gross profit: 111302630
Operating expenses (4)(35)(32)(25)(52)
Operating income (loss): (4)(24)(1)1(22)
Nonoperating income (expense) 1(0)320
Investment income, nonoperating 00110
Other nonoperating income (expense) 0(0)100
Interest and debt expense (0)(0)(0)(0)(0)
Other undisclosed income from continuing operations before equity method investments, income taxes 00000
Income (loss) from continuing operations before income taxes: (3)(24)23(22)
Income tax expense (benefit) (3)(1)3(2)2
Net income (loss) available to common stockholders, diluted: (6)(25)51(20)

Comprehensive Income ($ in millions)

9/30/2017
TTM
12/31/2016
12/31/2015
12/31/2014
12/31/2013
12/31/2012
Net income (loss): (6)(25)51(20)
Other comprehensive loss   (0)  
Comprehensive income (loss): (6)(25)51(20)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent (3)(3) 21
Comprehensive income (loss), net of tax, attributable to parent: (8)(28)53(19)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: